Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update
The Pharma Data
NOVEMBER 4, 2020
Initiated CTP-543 THRIVE-AA1 Phase 3 Trial in November 2020. Initial data from an ongoing long-term, open label extension study with CTP-543 were presented in the late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 29, 2020. G&A Expenses. .
Let's personalize your content